Florence Atrafi

432 total citations
18 papers, 322 citations indexed

About

Florence Atrafi is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Florence Atrafi has authored 18 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Genetics and 4 papers in Molecular Biology. Recurrent topics in Florence Atrafi's work include Cancer Treatment and Pharmacology (8 papers), Nanoparticle-Based Drug Delivery (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Florence Atrafi is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Nanoparticle-Based Drug Delivery (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Florence Atrafi collaborates with scholars based in Netherlands, United States and Spain. Florence Atrafi's co-authors include Ron H.J. Mathijssen, Cristianne J.F. Rijcken, Rob Hanssen, Ferry A.L.M. Eskens, Neeltje Steeghs, Stijn L.W. Koolen, Peter de Bruijn, Jan H.M. Schellens, Martijn P. Lolkema and Jos H. Beijnen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Advanced Drug Delivery Reviews.

In The Last Decade

Florence Atrafi

17 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florence Atrafi Netherlands	11	115	103	102	80	48	18	322
Shaomin Che China	12	64 0.6×	155 1.5×	112 1.1×	58 0.7×	57 1.2×	17	355
Veronika Ecker Germany	8	64 0.6×	180 1.7×	149 1.5×	46 0.6×	62 1.3×	12	404
Yusuke Ohara Japan	11	95 0.8×	152 1.5×	198 1.9×	80 1.0×	68 1.4×	53	465
Yun‐Long Tseng Taiwan	10	166 1.4×	186 1.8×	100 1.0×	76 0.9×	24 0.5×	14	357
Amirhossein Ahmadieh-Yazdi Iran	9	51 0.4×	107 1.0×	92 0.9×	65 0.8×	18 0.4×	22	289
Man Shu China	11	99 0.9×	101 1.0×	145 1.4×	121 1.5×	93 1.9×	25	418
Adrianus C. Laan Netherlands	13	50 0.4×	155 1.5×	145 1.4×	71 0.9×	85 1.8×	20	439
Ephraem Leitner Australia	7	45 0.4×	126 1.2×	34 0.3×	98 1.2×	39 0.8×	8	340
Wanting Hou China	9	29 0.3×	108 1.0×	121 1.2×	36 0.5×	73 1.5×	15	289
Jennifer A. Crozier United States	10	58 0.5×	137 1.3×	267 2.6×	48 0.6×	94 2.0×	34	474

Countries citing papers authored by Florence Atrafi

Since Specialization

Citations

This map shows the geographic impact of Florence Atrafi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Atrafi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Atrafi more than expected).

Fields of papers citing papers by Florence Atrafi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Atrafi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Atrafi. The network helps show where Florence Atrafi may publish in the future.

Co-authorship network of co-authors of Florence Atrafi

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Atrafi. A scholar is included among the top collaborators of Florence Atrafi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Atrafi. Florence Atrafi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Koolen, Stijn L.W., Cristianne J.F. Rijcken, Ruben A.G. van Eerden, et al.. (2025). Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical data. Biomedicine & Pharmacotherapy. 186. 118028–118028. 1 indexed citations

Matić, Maja, Arwin Ralf, B.J.C. van den Bosch, et al.. (2025). Recommendations for (Pharmaco)Genetic Sampling in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. Clinical and Translational Science. 18(8). e70303–e70303.

Frille, Armin, et al.. (2024). Lung cancer screening: where do we stand?. Breathe. 20(2). 230190–230190. 8 indexed citations

Rijcken, Cristianne J.F., Federica De Lorenzi, Rob Hanssen, et al.. (2022). Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles. Advanced Drug Delivery Reviews. 191. 114613–114613. 23 indexed citations

Atrafi, Florence, Ruben A.G. van Eerden, Stijn L.W. Koolen, et al.. (2021). Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634. Cancers. 13(15). 3741–3741. 10 indexed citations

Atrafi, Florence, Ruben A.G. van Eerden, Esther Oomen‐de Hoop, et al.. (2020). Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clinical Cancer Research. 26(14). 3537–3545. 45 indexed citations

Atrafi, Florence, Herlinde Dumez, Ron H.J. Mathijssen, et al.. (2020). A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours. Journal of Controlled Release. 325. 191–197. 39 indexed citations

Eerden, Ruben A.G. van, Florence Atrafi, Esther Oomen‐de Hoop, et al.. (2019). Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): The CriTax study. Annals of Oncology. 30. v184–v184. 3 indexed citations

Atrafi, Florence, Ruben A.G. van Eerden, Esther Oomen‐de Hoop, et al.. (2019). Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in patients with solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3096–3096. 2 indexed citations

10.

Atrafi, Florence, Herlinde Dumez, Ron H.J. Mathijssen, et al.. (2019). A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3026–3026. 13 indexed citations

11.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations

12.

Braal, C. Louwrens, Peter de Bruijn, Florence Atrafi, et al.. (2018). A new method for the determination of total and released docetaxel from docetaxel-entrapped core-crosslinked polymeric micelles (CriPec®) by LC–MS/MS and its clinical application in plasma and tissues in patients with various tumours. Journal of Pharmaceutical and Biomedical Analysis. 161. 168–174. 22 indexed citations

13.

Verheijen, Remy B., Bram Thijssen, Florence Atrafi, et al.. (2018). Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. Journal of Chromatography B. 1104. 234–239. 40 indexed citations

14.

Elst, Arja ter, Ron H.J. Mathijssen, Florence Atrafi, et al.. (2018). A single digital droplet PCR assay to detect multipleKITexon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget. 9(17). 13870–13883. 26 indexed citations

15.

Verheijen, Remy B., Florence Atrafi, Jan H.M. Schellens, et al.. (2017). Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. Clinical Pharmacokinetics. 57(5). 637–644. 22 indexed citations

16.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2017). Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.. Journal of Clinical Oncology. 35(15_suppl). 8530–8530. 4 indexed citations

17.

Elst, Arja ter, Ron H.J. Mathijssen, Florence Atrafi, et al.. (2017). Abstract 4951: Dynamics of KIT exon 11 mutations in cell free plasma DNA of patients treated for advanced gastrointestinal stromal tumors: Results from the Dutch GIST bio-databank. Cancer Research. 77(13_Supplement). 4951–4951. 1 indexed citations

18.

Amin, Ahmad S., Gerard J.J. Boink, Florence Atrafi, et al.. (2011). Facilitatory and inhibitory effects of SCN5A mutations on atrial fibrillation in Brugada syndrome. EP Europace. 13(7). 968–975. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact